GPT yields 0.75% · JNJ yields 2.14%● Live data
📍 JNJ pulled ahead of the other in Year 6
Combined, GPT + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GPT + JNJ for your $10,000?
GPT is designed to be highly dynamic, relying on both AI and human expertise to capitalize on evolving market opportunities. The strategy integrates human insight with AI-powered stock selection to construct a portfolio of global large-cap stocks. Portfolio construction begins with an analyst setting the portfolios parameters, including structure, concentration limits, and thematic inspiration from renowned trading strategies. AI then analyzes datasets to identify four to six major trading trends to choose positions that align with these trends based on key financial metrics such as revenue growth and earnings. Three independent AI models select 20 to 30 stocks to form an equal-weighted portfolio, with no single position exceeding 10%. The selection process combines both quantitative and qualitative analysis. Portfolio rebalancing is done quarterly to ensure compliance. The fund is expected to have a high portfolio turnover rate. Prior to Sept. 29, 2025, the fund name was Intelligent Livermore ETF and traded under the ticker LIVR.
Full GPT Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.